ArticleAvicenna journal of phytomedicine2026
Lycopene suppresses α-cypermethrin nephrotoxicity: An insight into its modulatory effect on oxidative stress-mediated pro-inflammation, DNA damage and caspase apoptosis in Wistar rats.
Article in Avicenna journal of phytomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Cypermethrin (CPM) is a synthetic pyrethroid pesticide with ubiquitous use in agriculture, but well associated with nephrotoxicity induction. However, CPM exposure is linked with human and animal systemic toxicity. Lycopene (LYP) is a lipid-soluble potent antioxidant abundant in tomatoes. The investigation thus explored whether LYP could mitigate CPM-induced nephrotoxicity via related mechanisms. Materials and Methods: The study design featured 4 groups: Control, LYP (10 mg/kg/day), CPM (25 mg/kg bw/day) and LYP (10 mg/kg bw/day) + CPM (25 mg/kg bw/day). The treatments of LYP and CPM were given for consecutive 28 days. Urea, uric acid and creatinine levels were estimated in serum, while glutathione peroxidase (GPx), catalase (CAT), and superoxide dismutase (SOD) activities, and malondialdehyde (MDA), DNA damage, cytokines, interleukin-10 (IL-10), interleukin-6 (IL-6), interleukin-4 (IL-4), and tumor necrosis factor-α (TNF-α), caspase-9 and caspase-3 levels were estimated in the renal tissue sample. Histopathology and its amelioration were analyzed. Results: The sub-acute CPM exposure provoked renal damage with significantly elevated levels of creatinine, uric acid, and urea. Renal antioxidant homeostasis was markedly impaired via depressed GPx, CAT, and SOD renal activities, and increased MDA level. Marked DNA damage and profound increases in the renal levels of caspase-9, IL-6, TNF-α, and caspase-3 were found, whereas the renal IL-4 and IL-10 levels were evidently reduced in comparison to the control. Interestingly, the LYP co-administration abrogated the CPM-induced oxidative stress, proinflammation, apoptosis, and DNA fragmentation. Conclusion: Our findings indicate that LYP supplementation may protect the kidney from oxidative stress-related attacks of CPM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.